Sign Up
Stories
AMX0035 for PSP: Phase 3 Trial Commences
Share
ALS Treatment Withdrawal: FDA Concerns
ARMGO Pharma's Positive Trial Results
Advancements in Cancer Treatment and Mar...
ADvantage Therapeutics Appoints Professo...
ANJESO Drug Insight and Market Forecast
AlzeCure's Drug Therapy Focus
Overview
API
Amylyx Pharmaceuticals initiates Phase 3 clinical trial for AMX0035 to treat Progressive Supranuclear Palsy (PSP), aiming to address the unmet needs of the PSP community.
Ask a question
How does Amylyx Pharmaceuticals' commitment to supporting and creating moments for the neurodegenerative community influence its approach to drug development?
How might the success of AMX0035 impact the treatment landscape for Progressive Supranuclear Palsy?
What are the potential implications of this trial for the broader field of neurodegenerative diseases?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage